A Trial of LNS8801 With or Without Pembrolizumab in Patients With Refractory Melanoma
Linnaeus Therapeutics, Inc.
Linnaeus Therapeutics, Inc.
Incyte Corporation
The Netherlands Cancer Institute
Celldex Therapeutics
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Massachusetts General Hospital
The Affiliated Hospital of Qingdao University
Peking University Cancer Hospital & Institute
GlaxoSmithKline
University of Utah
Bristol-Myers Squibb
Pfizer
FeRx